Jun 22, 2021 / 12:30PM GMT
Operator
Good morning, and good afternoon, and welcome to the Novartis Iptacopan Update. (Operator Instructions) A recording of this conference call, including the Q&A session, will be available on our website shortly after the call ends. (Operator Instructions) With that, I would like to hand over to Mr. Samir Shah, Head of Investor Head of Investor Relations. Please go ahead, sir.
Samir Shah - Novartis AG - Global Head of IR
Thank you very much, and welcome, everybody, and good morning and good afternoon as well. Thank you so much for taking the time to participate in this iptacopan update. People are a little surprised as to why we're doing an update on a single molecule. But as you'll see, and you probably know from having read some of the slides, it's because we've got a number of indications for iptacopan and we thought it was a good time around this stage to actually go through in a little more detail the various indications and the way we're trying to develop iptacopan in the 2 therapeutic areas of nephrology and hematology.
It's my great pleasure
Novartis AG Iptacopan (LNP023) Update Call Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers